Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för Charles S Berkman. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att Charles S Berkman har rapporterat innehav eller affärer i följande företag:
Värdepapper | Titel | Senaste rapporterade innehav |
---|---|---|
US:OABI / OmniAb, Inc. | Chief Legal Officer | 363 212 |
US:LGND / Ligand Pharmaceuticals Incorporated | 23 825 | |
CLO & Secretary, Director | 0 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av Charles S Berkman. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av Charles S Berkman som avslöjats för Securities Exchange Commission (SEC).
Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-04-07 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
S - Sale | −7 206 | 363 212 | −1,95 | 2,00 | −14 412 | 726 424 | |
2025-04-07 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 13 542 | 370 418 | 3,79 | ||||
2025-02-19 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
S - Sale | −7 255 | 356 876 | −1,99 | 3,67 | −26 626 | 1 309 735 | |
2025-02-19 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
S - Sale | −8 215 | 364 131 | −2,21 | 3,68 | −30 231 | 1 340 002 | |
2025-02-19 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 13 541 | 372 346 | 3,77 | ||||
2025-02-19 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 15 615 | 358 805 | 4,55 | ||||
2025-01-22 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
S - Sale | −25 489 | 343 190 | −6,91 | 3,24 | −82 584 | 1 111 936 | |
2025-01-22 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
A - Award | 45 294 | 368 679 | 14,01 | ||||
2024-12-10 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
S - Sale | −8 022 | 323 385 | −2,42 | 4,13 | −33 131 | 1 335 580 | |
2024-12-10 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 15 621 | 331 407 | 4,95 | ||||
2024-04-23 |
|
4/A | OABI |
OmniAb, Inc.
Common Stock |
A - Award | 366 511 | 305 412 | −599,86 | ||||
2024-04-09 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
S - Sale | −6 954 | 292 617 | −2,32 | 5,27 | −36 648 | 1 542 092 | |
2024-04-09 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 13 541 | 299 571 | 4,73 | ||||
2024-02-20 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
F - Taxes | −2 034 | 286 030 | −0,71 | 5,54 | −11 268 | 1 584 606 | |
2024-02-20 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 5 698 | 288 064 | 2,02 | ||||
2024-02-20 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
F - Taxes | −5 575 | 282 366 | −1,94 | 5,54 | −30 886 | 1 564 308 | |
2024-02-20 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 15 624 | 287 941 | 5,74 | ||||
2024-01-03 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
F - Taxes | −7 195 | 272 317 | −2,57 | 6,25 | −44 969 | 1 701 981 | |
2024-01-03 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 17 556 | 279 512 | 6,70 | ||||
2023-12-11 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
F - Taxes | −5 403 | 261 956 | −2,02 | 4,85 | −26 205 | 1 270 487 | |
2023-12-11 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
M - Exercise | 15 622 | 267 359 | 6,21 | ||||
2023-04-11 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
A - Award | 40 625 | 414 564 | 10,86 | ||||
2023-02-17 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
F - Taxes | −2 166 | 373 939 | −0,58 | 3,80 | −8 231 | 1 420 968 | |
2023-02-17 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
F - Taxes | −5 404 | 376 105 | −1,42 | 3,80 | −20 535 | 1 429 199 | |
2023-02-17 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
F - Taxes | −1 973 | 381 509 | −0,51 | 3,80 | −7 497 | 1 449 734 | |
2023-01-05 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
A - Award | 46 864 | 383 482 | 13,92 | ||||
2022-12-30 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
F - Taxes | −6 518 | 336 618 | −1,90 | 3,66 | −23 856 | 1 232 022 | |
2022-12-05 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
F - Taxes | −10 580 | 343 136 | −2,99 | 3,35 | −35 443 | 1 149 506 | |
2022-11-03 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | −11 944 | 23 825 | −33,39 | ||||
2022-11-03 |
|
4 | NONE |
OmniAb Operations, Inc.
Common Stock |
D - Sale to Issuer | −52 587 | 0 | −100,00 | ||||
2022-11-03 |
|
4 | NONE |
OmniAb Operations, Inc.
Common Stock |
A - Award | 15 409 | 52 587 | 41,45 | ||||
2022-11-03 |
|
4 | OABI |
OmniAb, Inc.
Common Stock |
A - Award | 353 716 | 353 716 | |||||
2022-06-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 5 375 | 35 769 | 17,68 | ||||
2022-05-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 20 126 | 20 126 | |||||
2022-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −577 | 30 394 | −1,86 | 123,68 | −71 363 | 3 759 130 | |
2022-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −633 | 30 971 | −2,00 | 123,68 | −78 289 | 3 830 493 | |
2022-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −368 | 31 604 | −1,15 | 123,68 | −45 514 | 3 908 783 | |
2022-01-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 326 | 31 972 | −3,98 | 113,68 | −150 740 | 3 634 577 | |
2022-01-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −830 | 33 298 | −2,43 | 113,68 | −94 354 | 3 785 317 | |
2022-01-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 3 836 | 34 128 | 12,66 | ||||
2022-01-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 2 401 | 30 292 | 8,61 | ||||
2021-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −442 | 27 891 | −1,56 | 172,46 | −76 227 | 4 810 082 | |
2021-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −368 | 28 333 | −1,28 | 172,46 | −63 465 | 4 886 309 | |
2021-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −205 | 28 701 | −0,71 | 172,46 | −35 354 | 4 949 774 | |
2021-02-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −18 097 | 28 906 | −38,50 | 178,50 | −3 230 376 | 5 159 819 | |
2021-02-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 6 955 | 6 955 | |||||
2021-02-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 3 491 | 47 003 | 8,02 | ||||
2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −830 | 43 512 | −1,87 | 156,01 | −129 488 | 6 788 307 | |
2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 2 401 | 44 342 | 5,72 | ||||
2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −509 | 41 941 | −1,20 | 156,10 | −79 455 | 6 546 990 | |
2021-01-27 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 1 335 | 42 450 | 3,25 | ||||
2020-07-01 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
J - Other | 238 | 41 115 | 0,58 | 89,03 | 21 189 | 3 660 427 | |
2020-06-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −11 146 | 40 877 | −21,43 | 118,59 | −1 321 775 | 4 847 497 | |
2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −367 | 52 023 | −0,70 | 97,23 | −35 683 | 5 058 196 | |
2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −207 | 52 390 | −0,39 | 97,23 | −20 127 | 5 093 880 | |
2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −307 | 52 597 | −0,58 | 97,23 | −29 850 | 5 114 006 | |
2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 17 220 | 17 220 | |||||
2020-02-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 3 835 | 52 904 | 7,82 | ||||
2019-12-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −546 | 49 069 | −1,10 | 105,87 | −57 805 | 5 194 935 | |
2019-12-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 1 335 | 49 615 | 2,77 | ||||
2019-12-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −585 | 48 280 | −1,20 | 105,87 | −61 934 | 5 111 404 | |
2019-12-26 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 1 693 | 48 865 | 3,59 | ||||
2019-08-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −424 | 4 153 | −9,26 | ||||
2019-08-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −669 | 1 948 | −25,56 | ||||
2019-08-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 424 | 47 172 | 0,91 | 85,79 | 36 375 | 4 046 886 | |
2019-08-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 669 | 46 748 | 1,45 | 56,26 | 37 638 | 2 630 042 | |
2019-07-02 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
J - Other | 182 | 46 079 | 0,40 | 97,03 | 17 659 | 4 470 930 | |
2019-02-13 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 14 649 | 14 649 | |||||
2019-02-13 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 3 202 | 45 897 | 7,50 | ||||
2019-01-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 1 412 | 42 695 | 3,42 | ||||
2019-01-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 1 370 | 41 283 | 3,43 | ||||
2019-01-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −1 931 | 0 | −100,00 | ||||
2019-01-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −675 | 2 617 | −20,50 | ||||
2019-01-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −244 | 0 | −100,00 | ||||
2019-01-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 675 | 39 913 | 1,72 | 56,26 | 37 976 | 2 245 505 | |
2019-01-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 931 | 39 238 | 5,18 | 74,42 | 143 705 | 2 920 092 | |
2019-01-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 244 | 37 307 | 0,66 | 21,92 | 5 348 | 817 769 | |
2018-12-17 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −3 400 | 244 | −93,30 | ||||
2018-12-17 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 3 400 | 37 063 | 10,10 | 21,92 | 74 528 | 812 421 | |
2018-10-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | −2 688 | 0 | −100,00 | ||||
2018-10-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −1 212 | 3 644 | −24,96 | ||||
2018-10-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 212 | 33 663 | 3,73 | 21,92 | 26 567 | 737 893 | |
2018-10-25 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 2 688 | 32 451 | 9,03 | 14,47 | 38 895 | 469 566 | |
2018-10-12 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | −2 000 | 2 688 | −42,66 | ||||
2018-10-12 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 2 000 | 29 763 | 7,20 | 14,47 | 28 940 | 430 671 | |
2018-09-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | X | −2 813 | 6 830 | −29,17 | |||
2018-09-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −2 813 | 27 763 | −9,20 | 250,69 | −705 181 | 6 959 812 |
2018-09-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 2 813 | 30 576 | 10,13 | 100,38 | 282 369 | 3 069 219 |
2018-09-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | X | −469 | 0 | −100,00 | |||
2018-09-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | X | −5 886 | 4 577 | −56,26 | |||
2018-09-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | X | −5 985 | 1 931 | −75,61 | |||
2018-09-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | X | −7 077 | 3 292 | −68,25 | |||
2018-09-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −19 417 | 27 763 | −41,16 | 254,99 | −4 951 065 | 7 079 179 |
2018-09-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 5 886 | 47 180 | 14,25 | 85,79 | 504 960 | 4 047 572 |
2018-09-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 7 077 | 41 294 | 20,68 | 56,26 | 398 152 | 2 323 200 |
2018-09-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 5 985 | 34 217 | 21,20 | 74,42 | 445 404 | 2 546 429 |
2018-09-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 469 | 28 232 | 1,69 | 21,92 | 10 280 | 618 845 |
2018-07-03 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
J - Other | 180 | 27 763 | 0,65 | 117,84 | 21 210 | 3 271 467 | |
2018-03-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −392 | 27 583 | −1,40 | 165,87 | −65 021 | 4 575 192 | |
2018-03-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 1 136 | 27 975 | 4,23 | ||||
2018-03-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 9 292 | 9 292 | |||||
2018-03-06 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 1 780 | 26 839 | 7,10 | ||||
2018-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −260 | 25 059 | −1,03 | 157,18 | −40 867 | 3 938 774 | |
2018-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −252 | 25 319 | −0,99 | 157,18 | −39 609 | 3 979 640 | |
2018-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −524 | 25 571 | −2,01 | 157,18 | −82 362 | 4 019 250 | |
2017-12-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
F - Taxes | −1 175 | 26 095 | −4,31 | 138,66 | −162 926 | 3 618 333 | |
2017-12-29 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 2 847 | 27 270 | 11,66 | ||||
2017-08-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −18 625 | 24 423 | −43,27 | 126,96 | −2 364 671 | 3 100 798 | |
2017-07-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
J - Other | 243 | 43 048 | 0,57 | 87,12 | 21 171 | 3 750 557 | |
2017-02-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 9 643 | 9 643 | |||||
2017-02-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 2 259 | 42 805 | 5,57 | ||||
2017-02-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 2 619 | 40 546 | 6,91 | ||||
2016-08-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −4 295 | 469 | −90,16 | ||||
2016-08-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −12 084 | 7 916 | −60,42 | ||||
2016-08-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −5 688 | 10 369 | −35,42 | ||||
2016-08-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −4 947 | 0 | −100,00 | ||||
2016-08-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −3 333 | 0 | −100,00 | ||||
2016-08-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 3 333 | 37 927 | 9,63 | 40,86 | 136 186 | 1 549 697 | |
2016-08-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 4 947 | 34 594 | 16,69 | 42,90 | 212 226 | 1 484 083 | |
2016-08-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −12 084 | 29 647 | −28,96 | 123,16 | −1 488 265 | 3 651 325 | |
2016-08-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 12 084 | 41 731 | 40,76 | 74,42 | 899 291 | 3 105 621 | |
2016-08-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −5 688 | 29 647 | −16,10 | 123,16 | −700 534 | 3 651 325 | |
2016-08-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 5 688 | 35 335 | 19,19 | 56,26 | 320 007 | 1 987 947 | |
2016-08-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −4 295 | 29 647 | −12,65 | 123,16 | −528 972 | 3 651 325 | |
2016-08-09 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 4 295 | 33 942 | 14,49 | 21,92 | 94 146 | 744 009 | |
2016-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 10 463 | 10 463 | |||||
2016-02-16 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 2 193 | 29 647 | 7,99 | ||||
2015-07-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −1 000 | 0 | −100,00 | ||||
2015-07-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 000 | 27 454 | 3,78 | 53,10 | 53 100 | 1 457 807 | |
2015-07-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | X | −8 442 | 4 688 | −64,30 | |||
2015-07-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | X | −5 625 | 0 | −100,00 | |||
2015-07-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −2 825 | 26 454 | −9,65 | 99,86 | −282 104 | 2 641 696 |
2015-07-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −8 838 | 29 279 | −23,19 | 99,18 | −876 553 | 2 903 891 |
2015-07-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −2 404 | 38 117 | −5,93 | 98,15 | −235 953 | 3 741 184 |
2015-07-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 8 442 | 40 521 | 26,32 | 14,47 | 122 156 | 586 339 |
2015-07-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 5 625 | 32 079 | 21,26 | 10,05 | 56 531 | 322 394 |
2015-07-01 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
J - Other | 465 | 26 454 | 1,79 | 45,67 | 21 237 | 1 208 167 | |
2015-03-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −4 130 | 4 764 | −46,44 | ||||
2015-03-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −1 134 | 0 | −100,00 | ||||
2015-03-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −4 130 | 25 989 | −13,71 | 74,58 | −308 015 | 1 938 260 | |
2015-03-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 4 130 | 30 119 | 15,89 | 21,92 | 90 530 | 660 208 | |
2015-03-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −1 134 | 25 989 | −4,18 | 74,58 | −84 574 | 1 938 260 | |
2015-03-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 134 | 27 123 | 4,36 | 14,47 | 16 409 | 392 470 | |
2015-03-18 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −6 000 | 25 989 | −18,76 | 74,51 | −447 060 | 1 936 440 | |
2015-03-18 |
|
4/A | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
J - Other | 126 | 27 433 | 0,46 | 45,23 | 5 699 | 1 240 753 | |
2015-02-11 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 16 057 | 16 057 | 56,26 | 903 367 | 903 367 | ||
2015-02-11 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 4 556 | 31 989 | 16,61 | ||||
2015-01-05 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 126 | 27 433 | 0,46 | 45,23 | 5 699 | 1 240 753 | |
2014-07-01 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 329 | 27 307 | 1,22 | 43,79 | 14 408 | 1 195 828 | |
2014-05-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −1 666 | 8 894 | −15,78 | ||||
2014-05-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −347 | 0 | −100,00 | ||||
2014-05-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −486 | 1 134 | −30,00 | ||||
2014-05-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −486 | 26 978 | −1,77 | 66,93 | −32 528 | 1 805 638 | |
2014-05-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 486 | 27 464 | 1,80 | 14,47 | 7 032 | 397 404 | |
2014-05-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −1 666 | 26 978 | −5,82 | 66,93 | −111 505 | 1 805 638 | |
2014-05-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 666 | 28 644 | 6,18 | 21,92 | 36 519 | 627 876 | |
2014-05-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −347 | 26 978 | −1,27 | 66,93 | −23 225 | 1 805 638 | |
2014-05-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 347 | 27 325 | 1,29 | 9,96 | 3 456 | 272 157 | |
2014-05-28 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −4 667 | 26 978 | −14,75 | 66,89 | −312 176 | 1 804 558 | |
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | −2 000 | 13 130 | −13,22 | ||||
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 2 000 | 31 645 | 6,75 | 14,47 | 28 940 | 457 903 | |
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −4 584 | 10 560 | −30,27 | ||||
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −1 166 | 0 | −100,00 | ||||
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −1 000 | 0 | −100,00 | ||||
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −4 779 | 0 | −100,00 | ||||
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −1 736 | 347 | −83,34 | ||||
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 20 000 | 20 000 | 74,42 | 1 488 400 | 1 488 400 | ||
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −386 | 4 947 | −7,24 | ||||
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −1 230 | 1 620 | −43,16 | ||||
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 736 | 29 645 | 6,22 | 9,96 | 17 291 | 295 264 | |
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −1 736 | 27 909 | −5,86 | 74,50 | −129 332 | 2 079 220 | |
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −1 230 | 29 645 | −3,98 | 74,50 | −91 635 | 2 208 552 | |
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 230 | 30 875 | 4,15 | 14,47 | 17 798 | 446 761 | |
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −4 779 | 29 645 | −13,88 | 74,50 | −356 036 | 2 208 552 | |
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 4 779 | 34 424 | 16,12 | 10,05 | 48 029 | 345 961 | |
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −4 584 | 29 645 | −13,39 | 74,50 | −341 508 | 2 208 552 | |
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 4 584 | 34 229 | 15,46 | 21,92 | 100 481 | 750 300 | |
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −1 000 | 29 645 | −3,26 | 74,50 | −74 500 | 2 208 552 | |
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 000 | 30 645 | 3,37 | 16,14 | 16 140 | 494 610 | |
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −1 166 | 29 645 | −3,78 | 74,50 | −86 867 | 2 208 552 | |
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1 166 | 30 811 | 3,93 | 21,00 | 24 486 | 647 031 | |
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −386 | 29 645 | −1,29 | 74,50 | −28 757 | 2 208 552 | |
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 386 | 30 031 | 1,30 | 42,90 | 16 559 | 1 288 330 | |
2014-02-14 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 2 500 | 29 645 | 9,21 | ||||
2014-01-02 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 209 | 27 145 | 0,78 | 33,92 | 7 088 | 920 623 | |
2013-09-04 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −3 834 | 0 | −100,00 | ||||
2013-09-04 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −9 499 | 3 834 | −71,24 | ||||
2013-09-04 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −4 862 | 0 | −100,00 | ||||
2013-09-04 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −11 804 | 4 862 | −70,83 | ||||
2013-09-04 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −7 020 | 2 850 | −71,12 | ||||
2013-09-04 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
M - Exercise | −312 | 5 625 | −5,26 | ||||
2013-09-04 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 312 | 26 936 | 1,17 | 10,05 | 3 136 | 270 707 | |
2013-09-04 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 4 862 | 26 624 | 22,34 | 16,14 | 78 473 | 429 711 | |
2013-09-04 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 3 834 | 21 762 | 21,39 | 21,00 | 80 514 | 457 002 | |
2013-09-04 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −7 020 | 17 928 | −28,14 | 47,54 | −333 726 | 852 285 | |
2013-09-04 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 7 020 | 24 948 | 39,16 | 14,47 | 101 579 | 360 998 | |
2013-09-04 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −11 804 | 17 928 | −39,70 | 47,54 | −561 154 | 852 285 | |
2013-09-04 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 11 804 | 29 732 | 65,84 | 16,14 | 190 517 | 479 874 | |
2013-09-04 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −9 499 | 17 928 | −34,63 | 47,54 | −451 576 | 852 285 | |
2013-09-04 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 9 499 | 27 427 | 52,98 | 21,00 | 199 479 | 575 967 | |
2013-08-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
M - Exercise | −4 284 | 5 937 | −41,91 | ||||
2013-08-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 4 284 | 17 928 | 31,40 | 10,05 | 43 054 | 180 176 | |
2013-08-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
M - Exercise | −14 583 | 2 083 | −87,50 | ||||
2013-08-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −14 583 | 13 644 | −51,66 | 42,63 | −621 732 | 581 698 | |
2013-08-20 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
M - Exercise | 14 583 | 28 227 | 106,88 | 9,96 | 145 247 | 281 141 | |
2013-07-01 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
P - Purchase | 815 | 13 644 | 6,35 | 17,36 | 14 148 | 236 860 | |
2013-05-13 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −4 000 | 12 829 | −23,77 | 26,66 | −106 640 | 342 021 | |
2013-02-19 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
A - Award | 15 144 | 15 144 | 21,92 | 331 956 | 331 956 | ||
2013-02-19 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Employee Stock Option (right to buy) |
A - Award | 4 856 | 4 856 | 21,92 | 106 444 | 106 444 | ||
2013-02-19 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 2 500 | 16 829 | 17,45 | ||||
2012-09-10 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −4 249 | 14 329 | −22,87 | 18,77 | −79 754 | 268 955 | |
2012-07-03 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
J - Other | 1 250 | 18 578 | 7,21 | 10,12 | 12 654 | 188 074 | |
2012-03-08 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −106 | 17 328 | −0,61 | 15,77 | −1 671 | 273 204 | |
2012-03-08 |
|
4 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
S - Sale | −3 500 | 17 434 | −16,72 | 15,76 | −55 160 | 274 762 | |
2012-02-13 |
|
4 | LGNDD |
LIGAND PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
A - Award | 9 870 | 9 870 | 14,47 | 142 819 | 142 819 | ||
2012-02-13 |
|
4 | LGNDD |
LIGAND PHARMACEUTICALS INC
Incentive Stock Option (right to buy) |
A - Award | 15 130 | 15 130 | 14,47 | 218 931 | 218 931 | ||
2012-02-13 |
|
4 | LGNDD |
LIGAND PHARMACEUTICALS INC
Common Stock |
A - Award | 5 000 | 20 934 | 31,38 | ||||
2012-01-06 |
|
4 | LGNDD |
LIGAND PHARMACEUTICALS INC
Common Stock |
J - Other | 1 238 | 15 934 | 8,42 | 10,09 | 12 491 | 160 766 | |
2007-03-09 | 3 | LGND |
LIGAND PHARMACEUTICALS INC
Common Stock |
1 263 |